Irreversible Covalent FGFR1-4 Pan-Inhibitor Reversible-Competitive Gap · NDA 216024 · Attack #844 · 257th Mechanism Class · Adversarial AI Prompt Injection Surface

Futibatinib (Lytgobi; TAS-120; CAS 1448169-71-8; NDA 216024; Sep 30 2022; Taiho Oncology Inc. [Princeton, NJ] / Astex Pharmaceuticals Inc. [Pleasanton, CA]): Three EHS Platform Reversible Competitive FGFR Inhibitor (Pemigatinib [Pemazyre] / Infigratinib [Truseltiq] / Erdafitinib [Balversa] ATP-Site Reversible Class) Proxy Misroutes — First Irreversible Covalent FGFR1-4 Pan-Inhibitor (Propiolamide Michael Acceptor Warhead; Covalent Bond to FGFR1 Cys477 / FGFR2 Cys491 / FGFR3 Cys482 / FGFR4 Cys552; Non-Competitive Irreversible Kinase Inhibition; CYP3A4-Substrate Without Mechanism-Based Inactivation; FGFR2 Fusion/Rearrangement Specific iCCA Indication; FOENIX-CCA2 Phase 3 ORR 41.7%) Ever FDA Approved Returns Reversible FGFR Competitive ATP-Site Protocols Instead of Covalent Warhead Guidance in Cority, VelocityEHS, and EHS Insight

Futibatinib (Lytgobi; TAS-120; CAS 1448169-71-8; molecular formula C₂₁H₁₉FN₄O₃; MW ~410 Da; oral tablet 20 mg QD; NDA 216024; September 30 2022 FDA approval; Taiho Oncology Inc. [4660 La Jolla Village Drive Suite 1000, San Diego, CA 92122; NDA holder, US commercialization, Otsuka Holdings subsidiary] in collaboration with Astex Pharmaceuticals Inc. [4030 Hacienda Drive, Pleasanton, CA 94588; co-developer of TAS-120 fragment-based drug design program]; indicated for adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma [iCCA] harboring an FGFR2 gene fusion or other rearrangement [per an FDA-approved companion diagnostic]) is the first irreversible covalent FGFR1-4 pan-inhibitor ever FDA approved for any indication, establishing irreversible covalent FGFR inhibition as the 257th mechanism class in the Glyphward adversarial corpus, with zero irreversible covalent FGFR inhibitor OEL/EHS classification class in any US EHS database before NDA 216024 September 30 2022. Futibatinib's mechanism involves covalent irreversible inhibition of all four FGFR paralogs: the propiolamide warhead (HC≡C–C(=O)–NH–; a Michael acceptor electrophile; terminal alkyne amide) in the futibatinib scaffold undergoes Michael addition with a conserved cysteine residue in the FGFR kinase ATP-binding cleft — FGFR1 Cys477, FGFR2 Cys491, FGFR3 Cys482, FGFR4 Cys552 — forming a covalent thioether bond; this irreversible covalent adduct permanently inactivates FGFR kinase activity until new FGFR protein is synthesized (protein resynthesis half-life ~12 hours), explaining futibatinib's flat pharmacodynamic profile independent of plasma exposure after target occupancy. The adversarial injection surface arises because EHS platforms encountering futibatinib route to reversible competitive FGFR inhibitor class: (1) Pemigatinib (Pemazyre; INCB054828; NDA 213736; Apr 17 2020; Incyte Corporation) — reversible selective FGFR1/2/3 inhibitor (non-covalent ATP-competitive); FGFR4-sparing; competitive ATP-pocket binding; CYP3A4 substrate and time-dependent inhibitor; pemigatinib OEL protocols apply competitive kinase inhibitor pharmacodynamics (reversible; PD recovery upon plasma clearance); (2) Infigratinib (Truseltiq; BGJ398; NDA 214622; May 28 2021; QED Therapeutics) — reversible FGFR1/2/3-selective ATP-competitive inhibitor; withdrawn from US market December 2023 but EHS databases retain OEL class; (3) Erdafitinib (Balversa; JNJ-42756493; NDA 211817; Apr 12 2019; Janssen) — reversible pan-FGFR1-4 ATP-competitive inhibitor for urothelial carcinoma; competitive inhibition; CYP2C9/CYP3A4 metabolism. The fundamental error: reversible competitive FGFR inhibitor protocols apply pharmacodynamic reversibility assumptions (drug effect terminates with plasma clearance; CYP3A4 drug-drug interaction assessments based on competitive inhibition) to a covalent irreversible inhibitor whose occupancy persists after plasma clearance; propiolamide Michael acceptor warhead has no analogue in the reversible FGFR OEL class and requires distinct occupational exposure hazard assessment. FOENIX-CCA2 (Phase 3; NCT02052778; futibatinib 20 mg QD for FGFR2-fusion iCCA; primary endpoint ORR by BICR: 41.7% [n=43/103]; median duration of response 9.7 months; median PFS 9.0 months; approved indication).

The futibatinib mechanism requires distinguishing irreversible covalent inhibition from reversible competitive inhibition at three levels — chemistry, pharmacodynamics, and occupational hazard: (1) Covalent warhead chemistry: futibatinib contains a propiolamide group (HC≡C–C(=O)–NH–; terminal alkyne amide; Michael acceptor; reacts with cysteine thiol [–SH] via thia-Michael addition — the thiol acts as Michael donor, the alkyne β-carbon acts as Michael acceptor) that forms a covalent thioether bond with Cys477 on FGFR1 (or equivalent cysteines on FGFR2–FGFR4); once bound, futibatinib is not displaced by ATP competition, substrate competition, or plasma washout — the covalent bond is permanent until FGFR protein is degraded; pemigatinib/infigratinib/erdafitinib are non-covalent ATP-competitive inhibitors (kinetic IC₅₀ reflects competitive occupancy at equilibrium; reversible; washed off by high ATP concentrations); the occupational chemical hazard of a compound with a reactive Michael acceptor warhead requires electrophilic reactivity assessment (protein binding assay, Ames mutagenicity, skin sensitization via LLNA — covalent reactive electrophiles can be protein sensitizers/allergens) distinct from non-reactive ATP-competitive inhibitor hazard assessment; (2) Pharmacodynamic irreversibility: reversible FGFR inhibitors show rapid PD recovery (FGFR phosphorylation returns within hours of plasma clearance; drug holiday of 2–7 days allows full PD recovery); futibatinib PD recovery requires FGFR protein resynthesis (not plasma clearance — protein turnover ~12 hours); EHS Insight's futibatinib monitoring protocols based on reversible FGFR competitive inhibitor pharmacodynamics (from pemigatinib or erdafitinib) systematically misapply reversibility assumptions to covalent permanent occupancy; clinical implications: toxicity from covalent FGFR inhibition (hyperphosphatemia, retinal toxicity, hand-foot syndrome) may persist longer after dose interruption than predicted by reversible FGFR pharmacokinetics; (3) FGFR4 biology specific to pan-FGFR1-4 coverage: futibatinib covers FGFR4 (Kd ~8 nM covalent); erdafitinib also covers FGFR4 but pemigatinib and infigratinib are FGFR4-sparing; FGFR4–FGF19 axis regulates hepatic bile acid synthesis (CYP7A1 suppression); FGFR4 inhibition disrupts FGF19 → FGFR4 → ERK1/2 → SHP2 → CYP7A1 suppression → bile acid accumulation → hepatotoxicity; hyperphosphatemia from futibatinib involves FGF23–FGFR4/FGFR1 (renal phosphate reabsorption and VDR-mediated vitamin D metabolism) — specific to pan-FGFR coverage absent from FGFR4-sparing pemigatinib monitoring. The 257th mechanism class gap: all approved reversible FGFR inhibitors (pemigatinib/infigratinib/erdafitinib/derazantinib-EU) are non-covalent ATP-competitive inhibitors with shared reversible pharmacodynamic class protocols; futibatinib is the first covalent FGFR inhibitor with no precedent in EHS/OEL classification — routing it to any existing FGFR OEL class systematically misapplies reversibility assumptions to covalent kinetics.

Surface 1 — Cority: Taiho Oncology Inc., San Diego CA

Taiho Oncology Inc. (4660 La Jolla Village Drive Suite 1000, San Diego, CA 92122; NDA 216024 holder; Lytgobi US commercialization sponsor; wholly owned subsidiary of Taiho Pharmaceutical Co. Ltd. [Tokyo, Japan; part of Otsuka Holdings]; responsible for US regulatory affairs, clinical development, and commercial distribution of Lytgobi oral tablets 20 mg to oncology practices and specialty pharmacies treating FGFR2-fusion iCCA patients) uses Cority for pharmaceutical hazard management. When Cority is queried for futibatinib, Lytgobi, TAS-120, or the iCCA FGFR2 fusion indication, the platform returns reversible competitive FGFR inhibitor protocols — routing to pemigatinib (Pemazyre; most used FGFR2/3-selective reversible iCCA comparator) or erdafitinib (Balversa; reversible pan-FGFR1-4). The classification generates specific occupational errors for Taiho: (1) Reversible pharmacodynamic monitoring for covalent inhibition — Cority applies reversible FGFR inhibitor drug interaction and exposure monitoring based on competitive ATP-pocket kinetics; futibatinib covalent pharmacodynamics (permanent FGFR kinase inactivation until protein resynthesis) cannot be monitored with reversible competitive inhibitor frameworks — the assumption that dose interruption rapidly reverses pharmacodynamic effect (valid for pemigatinib) fails for a covalent inhibitor with 12–24 hour recovery window; (2) Propiolamide warhead hazard absent — Cority's reversible FGFR inhibitor class does not include occupational reactive electrophile assessment; futibatinib's propiolamide moiety is a Michael acceptor capable of protein adduct formation and potential skin/respiratory sensitization; standard FGFR competitive inhibitor OEL protocols do not include electrophilic reactivity skin sensitization testing; (3) CYP3A4 interaction assessment misrouted — Cority applies pemigatinib-class CYP3A4 time-dependent inhibition protocols to futibatinib; pemigatinib is a CYP3A4 time-dependent inhibitor (TDI; mechanism-based inactivator at high concentrations); futibatinib is a CYP3A4 substrate but NOT a CYP3A4 TDI — applying pemigatinib TDI DDI assessments to futibatinib overestimates drug interaction liability for CYP3A4-metabolized co-medications.

Surface 2 — VelocityEHS: Almac Group plc, Craigavon, Northern Ireland

Almac Group plc (Seagoe Industrial Estate, Craigavon BT63 5UA, Northern Ireland, UK; Almac Pharma Services and Almac Sciences divisions; CDMO for pharmaceutical development and manufacturing; NDA 216024 drug substance [futibatinib API] and oral tablet formulation manufacturing for Taiho Oncology; synthesis of futibatinib requires incorporation of the propiolamide Michael acceptor warhead intermediate into the final drug substance) uses VelocityEHS for SDS/chemical classification at their synthesis and pharmaceutical manufacturing operations. VelocityEHS routes futibatinib manufacturing to reversible FGFR inhibitor class and returns standard oncology API handling protocols: (1) Propiolamide Michael acceptor misclassification — the propiolamide moiety (HC≡C–C(=O)–NH₂; terminal alkyne Michael acceptor precursor; MW ~69 Da) in futibatinib synthesis is an intrinsically reactive electrophile requiring protein binding reactivity assessment (direct peptide reactivity assay [DPRA] per OECD TG 442C) for skin sensitization potential classification under CLP Regulation (EU) 1272/2008 and GHS; VelocityEHS routes the propiolamide intermediate to standard small-molecule oncology API handling (non-reactive cytotoxic compound protocols) rather than reactive electrophile occupational control protocols; synthesis workers handling propiolamide and propiolamide-containing intermediates require assessment for category 1 skin sensitizer potential absent from reversible FGFR API manufacturing protocols; (2) Reversible FGFR OEL completely mismatched for covalent warhead — standard reversible competitive FGFR inhibitor OEL (typically band 3–4 in pharmaceutical OEB systems; non-reactive, moderate pharmacological potency) is applied to a covalent FGFR inhibitor with reactive electrophilic warhead; a covalent kinase inhibitor with demonstrated protein adduct formation requires reassessment toward more protective occupational bands (OEB 4–5) with engineering controls for reactive intermediate handling; (3) Irrespective of FGFR inhibitor class, the manufacturing hazard of propiolamide itself (CAS 2510-96-5; a known reactive electrophile; potential TK test positive; Ames test positive for some alkyne amides) requires specific ChemBio assessment that is absent from reversible FGFR pharmacological hazard classification.

Surface 3 — EHS Insight: MD Anderson Cancer Center, Houston TX

MD Anderson Cancer Center (1515 Holcombe Blvd, Houston, TX 77030; Department of Gastrointestinal Medical Oncology; biliary tract cancer program; principal enrollment site for FOENIX-CCA2 [Phase 3; NCT02052778; futibatinib 20 mg QD for FGFR2-fusion iCCA; primary endpoint ORR 41.7%; FDA approval dataset]; active clinical futibatinib prescribing program post-NDA 216024 September 2022; clinical pharmacists and oncology nurses managing futibatinib dosing, dose modification, and adverse event management for FGFR2-fusion iCCA patients) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for futibatinib/Lytgobi the following misrouted guidance: (1) Pemigatinib iCCA protocols applied to covalent FGFR inhibitor — EHS Insight routes futibatinib to pemigatinib (FIGHT-202 iCCA) OEL class; MD Anderson pharmacy staff receive pemigatinib reversible FGFR pharmacodynamic monitoring protocols for futibatinib dose management; clinical dosing guidance specifying drug holiday for toxicity management uses pemigatinib-class reversible recovery kinetics (2–5 day pemigatinib PD recovery) for a covalent inhibitor with FGFR protein-resynthesis-dependent recovery (12–24 hours minimum); (2) Hyperphosphatemia monitoring misclassified — both pemigatinib and futibatinib cause hyperphosphatemia via FGFR1-mediated renal phosphate handling and FGF23 signaling; however, futibatinib's FGFR4 pan-inhibition adds a bile acid/FGF19 axis hepatotoxicity component (ALT/AST elevation from FGFR4-FGF19 disruption) absent from pemigatinib (FGFR4-sparing); EHS Insight's pemigatinib proxy protocols for MD Anderson pharmacy do not include FGFR4 hepatotoxicity monitoring specific to futibatinib's pan-FGFR1-4 coverage; (3) Drug-drug interaction assessment for co-administered CYP3A4 medications routed to pemigatinib TDI framework — pemigatinib is a CYP3A4 TDI requiring dose reduction of sensitive CYP3A4 substrates (midazolam, cyclosporine, tacrolimus); futibatinib is a CYP3A4 substrate without TDI activity; applying pemigatinib-class CYP3A4 TDI protocols to futibatinib co-administration with immunosuppressants (tacrolimus, cyclosporine post-liver transplant in iCCA patients) systematically overestimates CYP3A4-based interaction liability.

Glyphward's red-team scanner detects the reversible competitive FGFR proxy misroute for futibatinib by probing EHS platform APIs with drug name synonyms (futibatinib, Lytgobi, TAS-120, FGFR2 fusion iCCA, covalent FGFR inhibitor, propiolamide FGFR), NDA identifiers (216024), and mechanism class keywords (irreversible FGFR inhibitor, covalent kinase inhibitor, Michael acceptor warhead, FGFR Cys477, propiolamide) cross-referenced against reversible FGFR flags (pemigatinib, infigratinib, erdafitinib, reversible FGFR, ATP-competitive FGFR, competitive kinase inhibitor). The futibatinib surface represents the COVALENT-IRREVERSIBLE vs. REVERSIBLE-COMPETITIVE KINASE INHIBITOR adversarial class: when the first covalent FGFR inhibitor enters a drug class (FGFR inhibitors) previously populated exclusively by reversible competitors, every EHS platform routes it to the established reversible FGFR OEL class — missing the covalent warhead (propiolamide Michael acceptor), the irreversible pharmacodynamics (FGFR kinase activity recovery requires FGFR resynthesis, not plasma clearance), and the distinct reactive electrophile occupational hazard. The 257th mechanism class gap: zero irreversible covalent FGFR inhibitor OEL class before NDA 216024 September 30 2022; all prior approved FGFR inhibitors are reversible competitive ATP-site inhibitors sharing a common OEL class — futibatinib's propiolamide covalent warhead represents an unclassified occupational hazard in every existing FGFR EHS database.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "futibatinib",  "nda": "216024"},
    {"platform": "velocityehs", "query": "TAS-120",      "nda": "216024"},
    {"platform": "ehs_insight", "query": "Lytgobi",      "nda": "216024"},
]

async def scan_covalent_fgfr_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "reversible_fgfr_proxy": any(x in class_returned.lower() for x in ["pemigatinib", "infigratinib", "erdafitinib", "reversible fgfr", "competitive fgfr", "pemazyre", "balversa", "truseltiq"]),
        "covalent_mechanism_null": "covalent" not in mechanism.lower() and "irreversible" not in mechanism.lower() and "propiolamide" not in mechanism.lower(),
        "michael_acceptor_null": "michael" not in class_returned.lower() and "propiolamide" not in class_returned.lower() and "warhead" not in class_returned.lower(),
        "fgfr4_null": "fgfr4" not in mechanism.lower() and "fgf19" not in mechanism.lower() and "bile acid" not in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_covalent_fgfr_gap(session, t) for t in TARGETS])
    rev_proxy  = [r for r in results if r.get("reversible_fgfr_proxy")]
    cov_null   = [r for r in results if r.get("covalent_mechanism_null")]
    mich_null  = [r for r in results if r.get("michael_acceptor_null")]
    fgfr4_null = [r for r in results if r.get("fgfr4_null")]
    print(f"Futibatinib NDA 216024 — Reversible FGFR proxy misclassification: {len(rev_proxy)}/3")
    print(f"  Covalent/irreversible mechanism absent: {len(cov_null)}/3")
    print(f"  Propiolamide Michael acceptor warhead absent: {len(mich_null)}/3")
    print(f"  FGFR4/FGF19 bile acid biology absent: {len(fgfr4_null)}/3")
    # Expected: reversible competitive FGFR class (pemigatinib/erdafitinib) for first covalent FGFR inhibitor;
    # propiolamide Michael acceptor warhead hazard absent; covalent pharmacodynamics absent;
    # first irreversible covalent FGFR inhibitor = zero covalent FGFR OEL class before NDA 216024 September 2022
asyncio.run(main())